Risk model identifies metastatic cancer patients who may benefit from immune checkpoint inhibitors
byUniversity of Eastern FinlandSurvival of the patients according to the risk scores. Kaplan-Meier curves illustrating overall survival (OS) (a) and progression-free survival (PFS) (b) according
Updated on: January 25,2024
24

Risk model identifies metastatic cancer patients who may benefit from immune checkpoint inhibitors
byUniversity of Eastern FinlandSurvival of the patients according to the risk scores. Kaplan-Meier curves illustrating overall survival (OS) (a) and progression-free survival (PFS) (b) according
Updated on:January 25,2024
24
